{"classes":[{"categories":[{"measurements":[{"comment":"The median duration of response is not estimable if less than half of the participants had an event (progression or death).","groupId":"OG000","lowerLimit":"525","upperLimit":"NA","value":"NA"}]}],"title":"mRECIST"},{"categories":[{"measurements":[{"comment":"The number of responders is not enough to estimate a standard error for the confidence interval.","groupId":"OG000","lowerLimit":"92","upperLimit":"NA","value":"525"}]}],"title":"RECIST"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Defined as time from first report of SD or better until disease progression or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"OG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"paramType":"MEDIAN","populationDescription":"The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.","reportingStatus":"POSTED","timeFrame":"Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months","title":"Phase 1 & Phase 2: Duration of Disease Control Based on RECIST v1.1 and mRECIST","type":"SECONDARY","unitOfMeasure":"days"}